Replimune Group Inc reports results for the quarter ended June 30 - Earnings Summary

Replimune

07/08/2025 18:31

Replimune Group Inc REPL.OQ reported a quarterly adjusted loss of 95 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -78 cents.  The mean expectation of nine analysts for the quarter was for a loss of 81 cents per share. Wall Street expected results to range from $-1.01 to -56 cents per share.

Reported revenue was zero​; analysts expected zero.

Replimune Group Inc's reported EPS for the quarter was a loss of 95 cents​.

The company reported a quarterly loss of $86.69 million.

Replimune Group Inc shares had fallen by 40.8% this quarter and lost 54.6% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 1% in the last three months.​

In the last 30 days, three analysts negatively revised earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 6 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is  "buy."

Wall Street's median 12-month price target for Replimune Group Inc is $4.00, about 37.5% below its last closing price of $5.50

This summary was machine generated from LSEG data August 7 at 05:30 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
-0.81
-0.95
Missed
Mar. 31 2025
-0.75
-0.82
Missed
Dec. 31 2024
-0.67
-0.79
Missed
Sep. 30 2024
-0.77
-0.68
Beat